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Abstract 
Vaccines and other alternative products are central to the future success of animal agriculture because they can 
help minimize the need for antibiotics by preventing and controlling infectious diseases in animal populations. To 
assess scientific advancements related to alternatives to antibiotics and provide actionable strategies to support their 
development, the United States Department of Agriculture, with support from the World Organisation for Animal 
Health, organized the second International Symposium on Alternatives to Antibiotics. It focused on six key areas: 
vaccines; microbial‑derived products; non‑nutritive phytochemicals; immune‑related products; chemicals, enzymes, 
and innovative drugs; and regulatory pathways to enable the development and licensure of alternatives to antibiotics. 
This article, the second part in a two‑part series, highlights new approaches and potential solutions for the develop‑
ment of vaccines as alternatives to antibiotics in food producing animals; opportunities, challenges and needs for the 
development of such vaccines are discussed in the first part of this series. As discussed in part 1 of this manuscript, 
many current vaccines fall short of ideal vaccines in one or more respects. Promising breakthroughs to overcome 
these limitations include new biotechnology techniques, new oral vaccine approaches, novel adjuvants, new deliv‑
ery strategies based on bacterial spores, and live recombinant vectors; they also include new vaccination strategies 
in‑ovo, and strategies that simultaneously protect against multiple pathogens. However, translating this research into 
commercial vaccines that effectively reduce the need for antibiotics will require close collaboration among stakehold‑
ers, for instance through public–private partnerships. Targeted research and development investments and concerted 
efforts by all affected are needed to realize the potential of vaccines to improve animal health, safeguard agricultural 
productivity, and reduce antibiotic consumption and resulting resistance risks.
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1 Introduction
Alternatives to antibiotics can help minimize the need 
for antibiotics by helping to prevent and control infec‑
tious diseases in animal populations. As such, safe and 
effective alternatives are crucially important to the future 
success of animal health and production. To assess scien‑
tific advancements in the research and development of 
alternatives to antibiotics, highlight promising research 
results and novel technologies, assess challenges associ‑
ated with their commercialization and use, and provide 
actionable strategies to support their development, the 
United States Department of Agriculture (USDA), with 
support from the World Organisation for Animal Health 
(OIE), organized the second International Symposium 
on Alternatives to Antibiotics. The symposium focused 
on six key areas: vaccines; microbial‑derived products; 
non‑nutritive phytochemicals; immune‑related products; 
chemicals, enzymes, and innovative drugs; and regula‑
tory pathways to enable the licensure and development of 
alternatives to antibiotics. This two‑part manuscript syn‑
thesizes and expands on the scientific presentations and 
expert panel discussions from the symposium regard‑
ing the use of vaccines as alternatives to antibiotics that 
can reduce the need for antibiotic use in animals. Part 1 
synthesizes and expands on the expert panel discussions 
regarding the opportunities, challenges and needs related 
to vaccines that may reduce the requirement for use of 
antibiotics in animals, while part two focuses on high‑
lighting new approaches and potential solutions.
A general discussion of the importance of antibiotic 
resistance and the opportunities, challenges and needs 
related to vaccines as alternatives that may reduce the 
need for use of antibiotics in animals is provided in part 
1 of this review, including a discussion of the proper‑
ties of ideal vaccines, how current vaccines compare 
to these ideal vaccines, and how investment decisions 
around research and development of vaccines are made. 
This second part of the manuscript will highlight specific 
research advancements in the area of veterinary vaccines.
2  New approaches for the development 
of veterinary vaccines
2.1  Mucosal immunity and tolerance: challenges 
to the development of effective oral vaccines
As mentioned in part one of this manuscript, most path‑
ogens invade the host at the mucosal surfaces, such as 
the gastro‑intestinal (GI) tract. The GI tract constitutes 
the largest surface area of the body and is exposed daily 
to vast numbers of foreign antigens derived from feed, 
the microbiota and pathogens [1]. Within the intes‑
tine a complex cellular network has evolved to prevent 
unwanted immune responses to innocuous antigens, for 
instance feed or microbiota, while allowing swift pro‑
tective responses against agents that cause infectious 
disease. Key to keeping enteric pathogens at bay is the 
presence of protective pathogen‑specific secretory IgA 
(SIgA) at the site of entry, which prevents the adhesion 
of micro‑organisms to the intestinal surfaces and neu‑
tralizes their enterotoxins. Triggering robust and protec‑
tive intestinal SIgA responses usually requires the local 
administration of vaccines [2]. Although live attenuated 
oral vaccines have had tremendous success, resulting for 
instance in the near global eradication of poliovirus [3], 
concerns on the dissemination of vaccine strains into the 
environment and rare cases of reversion to virulence, 
leading to vaccine‑induced disease, have driven oral vac‑
cine development to nonliving or vectored vaccines [4]. 
However, oral vaccination is challenging due to several 
hurdles imposed by the cellular and molecular architec‑
ture of the gut: (i) the harsh environment of the stom‑
ach and small intestine, including the low pH, digestive 
enzymes, and bile salts, required to digest feed also easily 
destroys vaccines, (ii) a poor uptake of vaccine antigens 
by the intestinal epithelial barrier and (iii) the tolerogenic 
mechanisms that pervade the intestinal tissues, leading to 
peripheral and oral immune tolerance upon oral admin‑
istration of antigens via the induction of  FoxP3+ regula‑
tory T cells. This often results in a low immunogenicity of 
oral vaccines and requires innovative strategies to deliver 
the vaccine antigens to the intestinal immune system as 
well as the inclusion of adjuvants that promote innate 
and adaptive immunity [5].
The mucosal immune system in the gut can be divided 
in inductive sites, where sampled antigens stimulate naive 
T and B cells, and effector sites, where effector cells per‑
form their functions, e.g. assisting in the production of 
SIgA. In the small intestine, the inductive sites comprise 
the gut‑associated lymphoid tissues (GALT) and the mes‑
enteric lymph nodes, while the effector sites constitute 
the lamina propria and the surface epithelium [6]. The 
GALT itself is composed of Peyer’s patches (PP), appen‑
dix and isolated lymphoid follicles. The presence of other 
GALT‑like structures, such as lymphocyte‑filled villi (rat, 
human) and cryptopatches (mouse) is dependent on the 
species. Interestingly, while in birds and most mammals 
PP or their equivalent are scattered throughout the small 
intestine, in pigs, ruminants and dogs the PP in the distal 
small intestine (ileum) are continuous. Fish and reptiles 
on the other hand lack PP and the intestinal immune sys‑
tem in these species is composed of epithelial leukocytes 
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and rare, small non‑organized lymphoid aggregates. It 
remains largely unknown how these species‑specific dif‑
ferences might affect the efficacy of oral vaccines.
From their entry point, which is typically the oral cav‑
ity, to their delivery site, most commonly the small intes‑
tine, the integrity of delivery systems and the stability of 
vaccine components are at risk. Lysozyme in saliva, the 
low gastric pH together with pepsin and intestinal pro‑
teases can degrade oral vaccines. Enteric coating of vac‑
cine components with pH‑responsive polymers with a 
dissolution threshold of pH 6 might protect against gas‑
tric degradation and results in the release of their con‑
tents in the small intestine [7]. In this context, ruminants 
pose an additional problem to vaccine stability as their 
polygastric gastro‑intestinal tract effectively degrades 
substances including vaccines. Site‑specific delivery of 
oral vaccines to the small intestine is favorable as the 
mucus layer covering the small intestinal epithelium 
consists of only one layer, which is loosely adherent, less 
thick and patchy as compared to the colonic mucus layers 
and might promote their access to the intestinal epithe‑
lium. In addition, the small intestine is less densely popu‑
lated by the microbiota, which might further disrupt the 
integrity of the delivery systems and the stability of vac‑
cine components. Underneath the mucus layer, a single 
layer of intestinal epithelial cells prevents uncontrolled 
access of the luminal content to the underlying intes‑
tinal tissues, further restricting uptake of oral vaccine 
antigens. Crossing of the epithelial barrier by vaccines 
could be enhanced by exploiting antigen sampling routes 
in the small intestine or by adopting strategies used by 
enteric pathogens to colonize or invade the host [8]. The 
best‑known sampling route in the gut is associated with 
microfold (M) cells. These specialized intestinal epithelial 
cells reside within the follicle‑associated epithelium cov‑
ering the Peyer’s patches and take up macromolecules, 
particulate matter and microorganisms [9]. Many enteric 
pathogens hijack M cells to invade the host by binding to 
apical receptors. For instance, the invasin protein of Yers-
inia species interacts with β1 integrin on M cells, leading 
to infection [10]. Likewise, GP2 marks M cells in many 
species and binds to FimH, a subunit of type I pili on 
Escherichia coli and Salmonella enterica. This interaction 
results in uptake of  FimH+ bacteria and initiates mucosal 
immunity [11]. Although many groups have focused on 
improving antigen uptake by targeting oral vaccines to 
M cell‑specific receptors, these cells represent only a 
small, species‑specific percentage of the total intesti‑
nal epithelial cell population. Although M cell numbers 
increase from the cranial to caudal small intestine and M 
cell targeting strategies work quite well in rodent mod‑
els, they mostly fail in larger animals due to the long 
passage time needed to reach the distal small intestine, 
where the gut‑associated immune system is most pro‑
nounced. Besides M cells, sampling of luminal antigens 
also occurs by intestinal mononuclear phagocytes via 
transepithelial dendrites. This sampling mainly occurs by 
 CD11c+CX3CR1+ macrophages, which transfer the anti‑
gens to  CD103+ dendritic cells (DCs). These DCs then 
drive the differentiation of regulatory T cells (Tregs), 
which subsequently induce tolerance to these proteins 
[12]. In the steady state, goblet cells can also transport 
small soluble proteins (<10 kDa) across the epithelium to 
tolerogenic DCs via so‑called goblet cell‑associated anti‑
gen passages [13]. Absorptive intestinal epithelial cells 
or enterocytes, constituting >90% of the small intestinal 
epithelium, may also sample the luminal content through 
receptor‑mediated transcytosis. For instance, the neo‑
natal Fc receptor (FcRn), an MHC class I‑like Fcγ recep‑
tor, is expressed on the apical surface of enterocytes and 
transcytoses IgG, immune complexes or Fc‑coated nano‑
particles from the lumen to the basolateral surface of the 
epithelium [14]. Similar to M cells, it might be worth‑
while to target apical receptors exploited by enteropatho‑
gens on small intestinal enterocytes to promote uptake of 
antigens by the epithelial barrier. A potential candidate 
would be aminopeptidase N (ANPEP), a zinc‑dependent 
peptidase present in the brush border of small intestinal 
enterocytes, which serves as an entry receptor for several 
coronaviruses and also binds F4 fimbriae, a colonisation 
factor produced by porcine‑specific enterotoxigenic E. 
coli. ANPEP also transports F4 fimbriae as well as micro‑
particles functionalised with ANPEP‑specific mono‑
clonal antibodies across the intestinal epithelial barrier, 
resulting in robust intestinal SIgA responses, at least in 
piglets [15, 16].
Although the selective targeting of vaccine antigens to 
apical receptors might promote their uptake by the epi‑
thelium via transcytosis, this process is in itself insuf‑
ficient to trigger protective intestinal immunity upon 
oral vaccination and explains the need to include adju‑
vants. These adjuvants should act on antigen presenting 
cells as well as intestinal epithelial cells to promote the 
induction of protective SIgA and cell‑mediated immune 
responses. Indeed, enterocytes not only provide a physi‑
cal barrier separating the intestinal lumen from the host 
tissues, but also relay information on the luminal con‑
tent to the underlying immune cells through the secre‑
tion of inflammatory or tolerogenic mediators. For 
instance, during the steady state, enterocytes produce 
thymic stromal lymphopoëtin (TSLP) and transform‑
ing growth factor (TGFβ), which imprint a tolerogenic 
phenotype on intestinal dendritic cells [17]. In contrast, 
upon infection enterocytes secrete IL‑6 and IL‑8 [18]. 
This probably facilitates a switch from a tolerogenic to 
an immune‑inductive environment, allowing activation 
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of intestinal antigen presenting cells. As yet the most 
effective adjuvants for oral application are the entero‑
toxins from Vibrio cholera (CT) and enterotoxigenic E. 
coli (ETEC) (LT). Due to inherent toxicity, dmLT was 
developed, a nontoxic LT mutant retaining its adjuvan‑
ticity. This dmLT triggered intestinal memory responses 
upon oral vaccination with a nonliving ETEC vaccine and 
seems a promising candidate to be included as adjuvant 
in oral vaccines [19, 20]. Similarly promising strategies 
have been reported for Eimeria [21]. Recent studies have 
shown that Eimeria‑induced IL‑17 production is critical 
in the initiation of early innate immune response in coc‑
cidiosis and blocking of IL‑17 production by exogenous 
IL‑17‑neutralizing antibody reduced both the intracellu‑
lar development of Eimeria and the severity of intestinal 
lesion [22–24].
In summarizing this part, future design of oral vac‑
cines should be tailored to the needs of the target species, 
focus on the selective delivery of vaccines to epithelial 
receptors to promote their transport across the epithelial 
barrier, induce protective immune response in the target 
tissues, and should include a mucosal adjuvant able to 
trigger memory SIgA responses.
2.2  Recombinant Bacillus spores as oral vectored vaccines
Endospores, or spores, are produced by many bacte‑
ria as a response to nutrient deprivation. The spore is a 
dormant entity about 1  μm in size that can germinate, 
allowing a nascent cell to emerge and enter vegetative 
cell growth [25]. The spore carries remarkable resistance 
properties, being typically resistant to high temperatures 
(typically 70–80  °C), desiccation, irradiation, and expo‑
sure to noxious chemicals [26]. The two principal spore‑
forming bacterial genera are Bacillus and Clostridia with 
the latter being exclusively anaerobic.
Members of the Bacillus genus are being used as pro‑
biotics, that is, microorganisms that are added to the diet 
to improve the balance of microbial communities in the 
GI‑tract and are therefore beneficial to human or animal 
health [27, 28]. Typical species include Bacillus clausii, 
Bacillus coagulans and Bacillus subtilis. For a long time, it 
has been assumed that Bacillus spores are soil organisms 
yet the evidence supporting this is actually rather sparse. 
Instead, spores are found in the soil in abundance but 
live, vegetative cells, are rarely if ever found other than 
in association with plants or in the animal gut. Mounting 
evidence shows that spores, although found in the soil, 
are mostly dormant and are shed in the feces of animals, 
which are their natural hosts [29]. The consumption of 
spores associated with soil‑contaminated plant matter 
enables spores to enter the GI‑tract, transit the gastric 
barrier unscathed and then germinate and proliferate in 
the intestine before excretion as dormant spores [30]. 
Evidence suggests that spore forming bacteria comprise 
as much as 30% of the gut microbiota, indicating that the 
ability to form spores enables bacteria to survive in the 
environment as well as entering and transiting the gastric 
barrier of animals [31].
The extraordinary resistance properties of Bacillus 
spores coupled with their ease of genetic manipulation, 
and their successful use as probiotics, makes them attrac‑
tive candidates for the delivery of heterologous antigens 
for vaccination. Spores have been used as vaccine vehi‑
cles in a number of ways, differing principally in whether 
spores are genetically modified or not. In all cases B. 
subtilis has been utilized due to the excellent genetics 
available. Using genetic modification, a chimeric gene 
consisting of a fusion between a B. subtilis anchor gene 
and an open reading frame encoding a putative protec‑
tive antigen is first constructed. The next step is intro‑
duction of the chimera into the B. subtilis chromosome 
using a gene transfer technique, typically DNA‑mediated 
transformation, a process in B. subtilis that is straight‑
forward. Typically, the anchor is the 5′‑end of a gene 
encoding a spore coat protein such that the chimera is 
displayed on the spore coat. Surprisingly, heterologous 
antigens displayed on B. subtilis spores are mostly sta‑
ble and do not appear to suffer extensive degradation. 
Using this approach a number of candidate antigens have 
been displayed and then evaluated in animal models. For 
example, spores displaying a tetanus antigen TTFC con‑
ferred protection to a lethal dose of tetanus toxin when 
administered orally [32, 33]. Mice dosed orally with 
spores expressing part of the alpha toxin of Clostridium 
perfringens were protected to challenge with alpha toxin 
[34]. A more recent example is that of Clostridium diffi-
cile where a C‑terminal fragment of the toxin A (TcdA) 
could be stably expressed and when administered orally 
to hamsters conferred protection to C. difficile infection 
[35, 36]. This particular vaccine has now entered clinical 
evaluation in humans [37].
Using a non‑genetically modified organism (GMO) 
approach it has been shown that spores can adsorb anti‑
gens efficiently onto their surface and surprisingly this 
is both strong and stable, and reflects the unique bio‑
physical properties of the spore [38]. For the adsorption 
approach, it has been shown that the gastric barrier is 
particularly corrosive and adsorbed antigens are labile, 
but for intranasal delivery this method appears satisfac‑
tory. Using this approach inactive (killed) spores can be 
used and success has included studies showing protec‑
tion to influenza (H5N1) [39] and significant reduction in 
lung counts of animals challenged with Mycobacterium 
tuberculosis [40]. A unique feature of spores is their abil‑
ity to enhance immune responses and this adjuvant effect 
has been characterized in depth [41–43].
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However, the use of spores as mass‑delivery vehicles 
for vaccines has several limitations. Oral delivery clearly 
is the preferred approach but appears to work effec‑
tively only for the GMO approach. Oral delivery also 
raises issues of tolerance and may prove to be a limiting 
factor. Sublingual delivery has also been explored; this 
approach appears to provide levels of protection that 
are equivalent to oral delivery, but requires more doses 
[36, 44]. Nasal delivery is suitable but raises potential 
safety issues. For animal vaccines, spores are attractive 
since they are currently used as feed probiotics but also 
because they can survive the high temperatures used 
for feed production and may offer long‑term utility. As 
mentioned already, spores have been manipulated for 
protection against C. perfringens but there now exists 
the opportunity to develop spores for protective vac‑
cination to necrotic enteritis, an important poultry dis‑
ease caused by C. perfringens that has been identified as 
a high vaccine research priority by the OIE ad hoc Group 
(see Additional file  2 in http://doi.org/10.1186/s1356 
7‑018‑0560‑8).
One application that is particularly promising is the 
use of spore vaccines in aquaculture. With intensive fish 
farming, Bacillus spores are being used as probiotic feed 
supplements. For shrimp farming, viral diseases have 
devastated the industry and one of the most important 
shrimp pathogens is white spot syndrome virus (WSSV) 
that causes seasonal outbreaks of disease [45]. A number 
of groups have developed B. subtilis spores that display 
the VP28 capsid protein of WSSV and when adminis‑
tered in feed appears to protect against white spot dis‑
ease [46–49]. The mechanism for protection is intriguing; 
even though shrimp are not thought to produce antibod‑
ies, it is clear that presentation of the viral antigens does 
produce some level of specific immunity.
Despite the progress being made with spore vac‑
cines one key issue remains: the containment of GMOs. 
Because spores are dormant with the potential to survive 
indefinitely in the environment, the use of recombinant 
spores in spore vaccines is likely to raise environmen‑
tal concerns and successful regulatory approvals may be 
slow or impossible to secure. For human use, it is likely 
that a case can be made that the recombinant spore vac‑
cines addresses an unmet clinical need, but for animal 
use devising a method for biological containment will be 
crucial.
2.3  Genetically modified live microorganisms as oral 
vectored vaccines and vaccine platforms
Technological advancements now make it possible to 
genetically engineer bacteria and other microorganisms 
that deliver heterologous antigens in a way that can stim‑
ulate mucosal as well as humoral and cellular systemic 
immunity [50]. Multiple species of bacteria including 
Salmonella Typhimurium, Salmonella Enteritidis, Sal-
monella Typhi, E. coli, Lactococcus lactis, Lactobacillus 
casei, Lactobacillus reuteri, Bacillus subtilis, and Bacillus 
thuringiensis, have been used to express protein antigens 
derived from bacterial, viral, and protozoal pathogens 
[51–61]. Some of these vectors are inherently non‑patho‑
genic; Lactobacillus and Lactococcus strains, for instance, 
are “Generally Recognized as Safe” (GRAS) [50, 61]. In 
other cases the microorganisms have been rendered non‑
pathogenic through the targeted deletion of virulence 
genes; strategies for the development of Salmonella vec‑
tors, for instance, typically rely on the deletion of certain 
metabolic functions that limit the bacterium’s ability 
to replicate in the host and attenuate virulence without 
impacting host colonization or invasion [50]. In fact, 
an intrinsic property shared by many, although not all, 
microorganisms used as vectors is their ability to effec‑
tively infect the host and initiate innate and subsequent 
adaptive immune responses, for instance by trigger‑
ing the host’s pattern recognition receptors [50]. These 
recombinant vectored vaccines can be delivered directly 
to a mucosal surface via nasal, ocular, or oral administra‑
tion, which not only allows for mass application but may 
also enhance mucosal immune responses, the primary 
surface through which most pathogens invade. Moreo‑
ver, contrary to traditional attenuated live vaccines, these 
recombinant vaccines in many cases do not carry a risk of 
reversion [50].
In veterinary medicine, oral vectored vaccines have 
been instrumental in the eradication or control of rabies 
in wildlife reservoirs [62, 63]. Oral vectored vaccines have 
also been developed for several other veterinary applica‑
tions, including some economically important diseases 
of food‑producing animals that are associated with con‑
siderable antibiotic use such as porcine circovirus type‑2 
(PCV‑2); in some cases, the vaccine vector is a chi‑
mera containing parts of multiple microorganisms—for 
instance, an attenuated live vaccine may be used as the 
vector—and the resulting vaccine simultaneously confers 
protection against multiple diseases, for instance Marek’s 
disease and infectious bursal disease or Newcastle dis‑
ease and avian influenza [63, 64].
The development of some vaccine vector systems has 
been very successful and numerous veterinary vaccines 
have been developed based on them; the canarypox 
virus vector system ALVAC, for instance, has been used 
for the development of a range of veterinary vaccines 
including against rabies, influenza, and West Nile virus 
[64]. Similarly, adenovirus vectors have also been widely 
used in veterinary medicine, both in companion and 
food‑producing animals [65]. Vaccine platforms such as 
these are particularly valuable as they can allow for the 
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rapid development of vaccine candidates in response to 
emerging vaccine needs, but the possibility of anti‑vec‑
tor immunity can restrict their usefulness [66]. Research 
and development of additional vaccine vector platforms 
is therefore needed. Salmonella strains that express for‑
eign antigens, either chromosomally or plasmid‑based, 
have yielded promising results in several species includ‑
ing mice, humans, pigs and chicken [67–72]. Diseases for 
which these Salmonella vectored vaccines were investi‑
gated include influenza, Brucella abortus, post‑weaning 
diarrhea and heterologous strains of Salmonella [69–72]. 
The use of Pasteurellaceae as vectors for modified live 
vaccines against shipping fever in calves is currently 
under investigation, with promising preliminary findings 
[73]. Use of this vector system for other diseases includ‑
ing pinkeye has been suggested [73].
2.4  New approaches for in‑ovo vaccines
In‑ovo vaccination is a mass‑vaccination strategy that is 
mainly used in broiler chickens albeit occasionally also in 
broiler‑breeder and layer chickens [74]. Eggs are injected 
in the hatchery, typically during the third week of embry‑
onic development around day 18 or 19. To vaccinate, a 
small hole is made in the shell at the blunt end of the egg 
and the vaccine is injected below the chorion‑allantoic 
membrane into the amniotic cavity or directly into the 
embryo. Commercial in‑ovo vaccination systems that 
automatically inject the eggs have been available since the 
early 1990s. More than 90% of broiler chickens in the US 
are vaccinated in ovo, and in Brazil that fraction equals 
70% [75]. The most common use of in‑ovo vaccination is 
for Marek’s disease, potentially combined with vaccines 
against other diseases such as Gumboro or Newcastle 
disease.
The ability to deliver a clearly defined vaccine dosage 
to every single chick and to invoke early protection in 
the chicks is among the main benefits of this technology, 
but it is labor‑intensive, causes stress for the chicks, and 
high sanitary standards need to be followed during vac‑
cine preparation and injection to manage infection risks 
[74, 76]. In addition, the location of the vaccine injection 
is critical for efficacy. It has been shown, for instance, 
that if Marek’s disease vaccine is accidentally deposited 
into the air cell or allantoic fluid, adequate protection is 
not achieved [77]. The stage of embryonic development 
can have profound effects on vaccine safety and efficacy 
[78]. One study, reported that vaccination of 10–12 day‑
old embryos with herpes virus of turkeys (HVT) led to 
pronounced lesions and embryonic deaths, while vacci‑
nation on days 16 did not cause detectable lesions [78]. 
Embryonic age at vaccination has also been shown to be 
correlated with antibody titers [79]. Maternal antibody 
titers actually increase after the typical age for in‑ovo 
vaccinations and peak just after hatch [76]. This can inter‑
fere with proper vaccine responses. However, evidence 
suggests that some vaccine strains are more affected by 
maternal antibodies than others [80]. Deliberate vaccine 
development may therefore limit the often disruptive 
effects that can be caused by maternal antibodies [78]. 
Other factors that need to be considered in the develop‑
ment of a successful in‑ovo vaccination program include 
the characteristics of the vaccine or vaccines to be used, 
the type of incubator in which the eggs are housed in the 
hatchery, and the breed and age of the parent flock [76].
In‑ovo vaccination strategies are promising means of 
reducing antibiotic use in poultry production and have 
been the subject of intense research. Importantly, they 
can provide robust and early protection against immune 
suppressive diseases such as infectious bursal disease [81, 
82] and vaccines against multiple diseases have been suc‑
cessfully combined. For instance, studies have shown that 
in‑ovo vaccination strategies can simultaneously confer 
protective immunity against Marek’s disease, infectious 
bursal disease, Newcastle disease, fowl poxvirus, coccidi‑
osis, and necrotic enteritis [83, 84]. Other combination 
vaccines under investigation include vectored vaccines 
that simultaneously provide protection against Newcastle 
disease and infectious bursal disease [85]. In‑ovo vaccina‑
tion strategies have also been explored for other poultry 
diseases with promising results. This included an avian 
influenza vaccine based on a non‑replicating human ade‑
novirus vector [86], a recombinant viral vector vaccine 
against infectious laryngotracheitis [87], recombinant 
protein Eimeria vaccines [84, 88, 89] and a fowl adeno‑
virus vectored vaccine against inclusion body hepatitis 
[90], among many others. A Mycoplasma gallisepticum 
vaccine for in‑ovo vaccination of layer chickens has also 
recently been evaluated, even though high chick losses at 
hatch were reported for the medium and high doses of 
the vaccine that were investigated [91]. Therefore, in‑ovo 
vaccination strategies are capable of controlling several 
economically important poultry diseases. Many of these 
diseases are viral, but can predispose animals to second‑
ary bacterial infections. Therefore, in many cases, in‑ovo 
vaccines are promising alternative approaches to the use 
of antibiotics.
3  Vaccination strategies to reduce antibiotic use 
for diseases from ubiquitous pathogens
3.1  Towards the development of new Clostridium 
perfringens vaccines
Clostridium perfringens is widespread in the environ‑
ment and in the gastrointestinal tract of most mammals 
and birds. However, this bacterium is also one of the 
most common pathogens of food‑producing animals, 
causing disease only under circumstances that create an 
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environment which favors growth and toxin production, 
such as stress, injury, or dietary changes [92]. The bac‑
terium itself is not invasive, but causes disease through 
the production of a wide array of toxins and enzymes. 
However, no single strain produces this entire toxin rep‑
ertoire, resulting in considerable variation in the toxin 
profiles and disease syndromes produced by different 
toxinotypes of this bacterium [93]. While some of these 
toxins act only locally, other toxins which are produced in 
the gut exert their action in other internal organs or can 
act both locally and systemically [94–96]. To date, effica‑
cious vaccines are only available for the diseases caused 
by systemic action of the toxins and vaccination against 
enteric diseases still remains a challenge. However, some 
of these enteric diseases caused by C. perfringens are of 
major economic importance and lead to considerable 
use of antibiotics. Amongst them are necrotic enteritis 
in broilers and necro‑haemorrhagic enteritis in calves. 
Despite the fact that much research is being directed to 
the development of novel vaccines against these C. per-
fringens‑induced enteric diseases, several key barriers 
still have to be overcome.
In general, clostridial vaccines require multiple doses 
to achieve full immunity. Unfortunately, parenteral 
booster immunizations are impossible in the broiler 
industry, where mass parenteral vaccination is only fea‑
sible at the hatchery, either in ovo or on day‑old chicks. 
Because single parenteral vaccination at day of hatch 
offers no protection, other delivery methods need to be 
developed [97]. Oral vaccines can more easily be admin‑
istered to birds, without the need of individual handling 
of the chicks and are therefore recommended. However, 
some questions arise when developing an oral vaccine 
as compared to the parenteral administration route. In 
addition to the fact that maternal antibodies can block 
the immune response in young chicks, also the induc‑
tion of oral tolerance has to be circumvented and an effi‑
cient way to present the antigens to the mucosal immune 
system has to be developed. Oral tolerance is a common 
problem in mammals and fish when developing oral vac‑
cines. This is in contrast to chickens, where oral tolerance 
is age‑dependent, and only an issue in 1‑ to 3‑day‑old 
chicks. After that age, protein antigens have been shown 
to induce a robust immune response and oral vaccina‑
tion schemes are thought to be feasible [98]. One appeal‑
ing strategy for the delivery of vaccine candidates to the 
mucosal immune system is the use of attenuated or aviru‑
lent bacteria as antigen vehicles [99]. Attenuated recom‑
binant Salmonella strains which express C. perfringens 
antigens have been tested in several studies as oral vac‑
cine vectors, leading to some promising results. However, 
the amount of protection afforded by these vaccines is 
not as high as compared to multiple doses of parenteral 
vaccination, and seems to depend on the colonization 
level and persistence of the vaccine strain [100–103]. This 
indicates that the use of live vectors to express antigens 
derived from C. perfringens strains in the gut of broilers 
is a promising approach, but the vaccine delivery strat‑
egy still needs to be optimized to achieve optimal antigen 
presentation to the mucosal immune system and provide 
improved protection. Alternatives to attenuated Salmo-
nella strains can be Bacillus subtilis spores or Lactobacil-
lus casei, which both have a GRAS status and have the 
potential to be used as vaccine carriers for Clostridium 
antigens [34, 104]. B. subtilis has the advantage that the 
heat‑stable spores can easily be incorporated in the feed 
and L. casei has known probiotic effects that facilitate 
the development of mucosal immunity. However, these 
types of vectors still have to be tested for their capacity 
to induce a good immune response, in particular against 
heterologous antigens, in broilers and whether they are 
able to provide protection against necrotic enteritis.
Another issue to be addressed when developing a vac‑
cine against C. perfringens‑induced enteric diseases is the 
choice of the antigens to be included in the vaccine. C. 
perfringens‑induced diseases are the result of the toxins 
and enzymes that are produced and vaccination of chicks 
with C. perfringens supernatants provides protection 
against experimental necrotic enteritis [97, 105]. How‑
ever, the protective capacity of the supernatants depends 
on the strain used for supernatant preparation, indicating 
that full protection might be determined by an effective 
combination of different bacterial immunogens [105]. In 
order to elucidate the optimal mixture of antigens to pro‑
tect against necrotic enteritis, challenge trials are being 
performed mostly using parenteral vaccination schemes. 
Once the ideal combination of antigens is known, this 
will have to be adapted to oral delivery strategies. Several 
C. perfringens antigens have been evaluated as potential 
vaccine candidates. The tested antigens include both C. 
perfringens toxins (e.g. alpha toxin and the NetB toxin) 
and highly immunodominant proteins identified in post‑
infection serum from birds immune to necrotic enteritis 
[106]. In general, immunization studies of broilers with 
a single antigen all resulted in some level of protec‑
tion against experimental necrotic enteritis. Remark‑
ably, immunization with NetB toxin, which is essential 
to cause disease in broilers, does not afford higher levels 
of protection than vaccination with other toxins or pro‑
teins. However, when birds were vaccinated either via the 
parenteral or the oral route, with a combination of both 
NetB toxin and alpha toxin, higher levels of protection 
were obtained [107, 108]. In order to obtain full protec‑
tion against C. perfringens‑induced enteric diseases, 
not only antibodies that inhibit toxin activity might be 
needed; a combination of antigens targeting also bacterial 
Page 8 of 15Hoelzer et al. Vet Res  (2018) 49:70 
proliferation, colonization and/or nutrient acquisition 
could be more efficient than either one of the individ‑
ual approaches. Indeed, in a recent study disruption of 
the putative adhesin‑encoding gene cnaA resulted in a 
reduced ability to colonize the chicken intestinal mucosa 
and to cause necrotic enteritis [109]. This strengthens 
the idea that vaccine antigens that target bacterial colo‑
nization might be indispensable to obtain a working 
vaccine against C. perfringens–induced enteric diseases. 
Additional vaccine targets might be enzymes that aid in 
breakdown of the host tissue and nutrient acquisition, 
such as, amongst others, mucinases, collagenases and 
hyaluronidases.
In contrast to the extensive efforts to develop a vac‑
cine against necrotic enteritis in chickens, considerably 
less research has been directed to vaccination against 
necro‑haemorrhagic enteritis in calves. The recent 
demonstration of the essential role of alpha toxin in 
necro‑haemorrhagic enteritis and the proposition of 
a pathogenesis model will allow for the more targeted 
development of a vaccine [110, 111]. In calves as in chick‑
ens, protection against C. perfringens‑induced necrosis 
can be obtained by antibodies against a mixture of toxins, 
at least in an experimental model for bovine necro‑haem‑
orrhagic enteritis [112]. Furthermore, antibodies against 
alpha toxin alone, which is essential to cause intestinal 
disease in calves, are not sufficient to provide the same 
level of protection as antibodies directed against a mix‑
ture of C. perfringens proteins, indicating that a mixture 
of different antigens will be needed to provide full pro‑
tection [110]. In order to fully protect calves against C. 
perfringens‑induced enteric diseases, antigens that target 
bacterial colonization and proliferation might be of equal 
importance as antigens targeting the toxin activities. 
Next, it has to be explored whether parenteral vaccina‑
tion is sufficient to induce a protective immune response 
or if a combination of systemic and mucosal immunity is 
needed when not only the bacterial toxins but also bacte‑
rial colonization is targeted.
As administration of multiple parenteral doses of a vac‑
cine to calves is more feasible than for chicken, it may 
be assumed that the development of a vaccine against 
necro‑haemorrhagic enteritis is more straightforward 
and that C. perfringens supernatants can be used as a 
vaccine preparation. However, native toxins cannot be 
used as vaccine antigens due to safety issues. Inactiva‑
tion of clostridial toxins is generally achieved by formal‑
dehyde treatment, which risks residual formaldehyde in 
the vaccine preparation, incomplete inactivation of the 
toxins, and batch‑to‑batch variation. Moreover, formal‑
dehyde inactivation can induce changes in the tertiary 
protein structures of relevant antigens and influence the 
immunogenicity of the vaccines. Indeed, vaccination of 
both chickens and calves with formaldehyde inactivated 
C. perfringens supernatants or toxins have resulted in a 
good antibody response, but these are unable to protect 
against intestinal disease [97, 112]. To overcome the need 
of chemically inactivating the C. perfringens toxins, cur‑
rent research focusses on the use of recombinant toxoids 
to develop a vaccine against C. perfringens‑induced dis‑
eases. While this may be a good strategy to obtain a safe 
and protective vaccine on a laboratory scale, the produc‑
tion process is more laborious and time‑consuming than 
production of conventional toxoids, especially because of 
the required purification steps [113]. Therefore, recent 
studies have explored the use of efficient low‑cost alter‑
natives, such as non‑purified recombinant clostridial 
toxins and even recombinant bacterins, with success 
[114–116].
In summary of this section, considerable progress has 
recently been made in the development of efficacious 
vaccines against C. perfringens‑induced enteric diseases. 
The main issue that hampers a breakthrough in this field 
is the identification of a defined combination of antigens 
that is able to provide full protection against disease. 
These antigens will most likely target both the bacterial 
toxins and the bacterial colonization and proliferation. 
For the broiler industry, once the ideal vaccine antigens 
have been identified, development of an oral vaccine is 
needed.
3.2  Towards the development of new coccidiosis vaccines
Coccidiosis, an enteric disease cause by protozoan para‑
sites of the genus Eimeria, remains a major economic and 
welfare concern for the poultry industry globally. Seven 
species (Eimeria acervulina, E. brunetti, E. maxima, E. 
mitis, E. necatrix, E. praecox and E. tenella) are known to 
infect chickens, and at least six others infect turkeys [117, 
118]. The costs associated with coccidial disease are diffi‑
cult to calculate, but have been estimated to exceed 3 bil‑
lion US dollars for the chicken industry alone, worldwide 
[119]. Because coccidiosis is a predisposing factor for the 
occurrence of necrotic enteritis, the true economic bur‑
den is likely even higher. All Eimeria species can cause 
disease but the severity and clinical symptoms vary 
among species, and there is little or no cross‑protection 
across species or some strains [120, 121].
3.2.1  Management of coccidiosis through anticoccidial 
drugs
Modern poultry production systems require effective 
control of coccidian parasites, typically through the rou‑
tine use of anticoccidial drugs in feed or water. In the 
European Union, eleven different anticoccidial drugs 
are currently licensed and between 240 and 300 tonnes 
are sold for use in animals for markets such as the UK 
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every year [122]. Anticoccidial drugs can be divided into 
two groups, synthetic or chemical anticoccidials and 
ionophores, which are products of fermentation [123]. 
In some countries such as the US, ionophores are clas‑
sified as antibiotics, albeit with low human medical 
importance.
The ionophores currently dominate the anticoccid‑
ial drug market, largely because they provide incom‑
plete protection, even against naïve field strains without 
any drug resistance. Low levels of parasites survive and 
induce protective immunity against the prevailing local 
parasite strains, without causing clinical disease [124]. 
Anticoccidial drugs provide an efficient means of con‑
trolling coccidial parasites and are highly cost‑effective. 
However, drug resistance is widespread and increasing 
consumer concerns related to drug use in livestock pro‑
duction and residues in the food chain encourage the use 
of alternatives such as vaccination. Notably, because coc‑
cidiosis is a predisposing factor for necrotic enteritis and 
other secondary bacterial infections, efficient control of 
this parasite is important to minimize the use of medi‑
cally important antibiotics, including those deemed criti‑
cally important for human health, in poultry production.
3.2.2  Traditional live anticoccidial vaccines
The first anticoccidial vaccine was marketed in 19521 
[125]. It is a live parasite vaccine which includes mul‑
tiple wild‑type (i.e., non‑attenuated) Eimeria species. 
Exposure to limited levels of such non‑attenuated para‑
sites permits the induction of a natural immune response 
in the chicken, resulting in protection against subse‑
quent coccidial challenge. However, because protec‑
tive immune responses against Eimeria are fully species 
specific, the inclusion of each individual target species is 
necessary if comprehensive protection is to be achieved, 
which results in relatively complex vaccine formulations. 
Such vaccines commonly include between three and 
eight parasite species or strains. The approach has been 
highly successful, although the lack of attenuation has 
been associated with reduced flock performance follow‑
ing vaccination and occasional clinical disease (reviewed 
elsewhere [126]).
In response to this limitation, a second generation of 
live Eimeria vaccines has been developed using attenu‑
ated parasite lines. For most of these vaccines, attenua‑
tion was achieved by selecting for so‑called precocious 
strains, which typically exhibit reduced pathogenicity 
with fewer and/or smaller rounds of asexual replication. 
These attenuated strains retained their ability to immu‑
nize. The first live attenuated anticoccidial vaccine was 
launched in 1989,2 and several similar vaccines have been 
developed since using the same approach [126]. Non‑
attenuated and attenuated anticoccidial vaccines have 
become popular in the breeder and layer sectors, but are 
less widely used in the much larger broiler sector due to 
their relatively high cost compared to anticoccidial drugs 
and their limited availability. Because Eimeria cannot 
replicate effectively in vitro, the production of these live 
vaccines can only be achieved in Eimeria‑free chickens 
and separate chickens have to be used for each species or 
strain to be included in a vaccine. Despite these produc‑
tion concerns billions of anticoccidial vaccine doses are 
sold every year, but more would be required to fully meet 
the growing demand.
3.2.3  Next generation anticoccidial vaccines
Efforts to improve on first and second generation live 
anticoccidial vaccines have included extensive attempts 
to identify antigens that are appropriate for use in sub‑
unit or recombinant vaccines. In addition, progress has 
been made on the preparation of novel adjuvants and 
some promising results have been obtained, although 
data on their use in poultry has so far remained fairly 
limited [127]. As an example, one vaccine3 is formulated 
from a crude mix of affinity purified E. maxima game‑
tocyte antigens [128], although the levels of protection 
achieved have remained controversial and production 
of the vaccine still requires parasite amplification in 
chickens. Numerous studies have suggested that defined 
antigens such as apical membrane antigen 1, immune 
mapped protein 1, lactate dehydrogenase and SO7 are 
highly promising vaccine candidates (reviewed elsewhere 
[129]). Studies of Eimeria field populations have reported 
limited diversity in many of these antigens, indicating 
that recombinant vaccines for Eimeria may succeed even 
though antigenic diversity has undermined equivalent 
vaccines for related parasites such as Plasmodium [130, 
131]. However, at present no recombinant anticoccidial 
vaccine is close to reaching the market.
One of the biggest remaining challenges is how to 
deliver the antigens in an affordable, effective, and, most 
importantly, scalable manner. A range of vectored expres‑
sion/delivery systems have been suggested including 
Fowlpox virus (FWPV), HVT, Salmonella Typhimurium, 
yeasts such as Saccharomyces cerevisiae and the tobacco 
plant Nicotiana tabacum, with several showing promise 
[129]. Most recently, it has been suggested that Eimeria 
itself might function as an expression/delivery vector 
for vaccine antigens [132–134]. The ability to express 
1 Under the name CocciVac™.
2 Under the name Paracox™.
3 Under the name CoxAbic™.
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and deliver anticoccidial vaccine antigens from multiple 
parasite species in a single transgenic line could provide 
an opportunity to streamline anticoccidial vaccine pro‑
duction from as many as eight lines to just one or two. 
Using an attenuated vector species such as E. acervulina 
can improve productive capacity enormously and reduce 
vaccine cost. The parasite vector may also provide some 
ability as an adjuvant and methods for on‑farm delivery 
are well established [133].
In summary of this section on new coccidiosis vaccines, 
as pressure to reduce antibiotic drug use in livestock pro‑
duction increases it is clear that the demand for coccidial 
vaccines is stronger than ever. In the US, approximately 
35–40% of broiler companies use programs that include 
vaccination to control coccidiosis [135]. This trend is 
primarily driven by demands to produce “no antibiot‑
ics ever” poultry products. However, it has also been 
shown that some coccidial vaccines provide an opportu‑
nity to replace drug‑resistant field parasites in a poultry 
house with susceptible vaccine strains. While current 
European attenuated vaccines are limited by their lower 
reproductive potential, live vaccines do retain consider‑
able unexplored potential. A better understanding of the 
underlying immune mechanisms through which these 
nontraditional approaches operate is needed to allow fur‑
ther progress. Ultimately, it is clear that novel vaccines 
must be cost‑effective, compatible with high standards of 
animal welfare, scalable and easy to deliver.
4  Autogenous vaccines to reduce the need 
for antibiotic use
Autogenous vaccines (AV) are also known as emergency, 
herd‑specific or custom made vaccines. Although the 
legal basis and exact definition differs from country to 
country, AVs are used worldwide (e.g. EU, USA, Canada, 
Brazil, China, Indonesia, Australia, Egypt) and have a 
long history of use. The use of AVs for the control of fowl 
cholera has been well‑documented [136, 137]. As a com‑
mon definition, all AVs are made from inactivated bac‑
terial or viral strains which were isolated from the same 
flock in which the vaccine is to be used. The use of AVs 
is only allowed if no licensed vaccine is available, or it 
is respectively ineffective or does not cover the current 
pathogen strains in the flock. The definition of a flock 
varies and may include integrated concepts of produc‑
tion chains in different places; to address the issue, the 
concept of an epidemiological link has recently been pro‑
posed by the Co‑ordination Group for Mutual Recogni‑
tion and Decentralised Procedures [138].
Licensed vaccines have advantages compared to AVs, 
including obligatory good manufacturing practice (GMP) 
production. Licensed vaccines are also produced in big‑
ger batches with defined strains and a high level of 
quality which makes their efficacy and safety predictable. 
However, licensed vaccines are not available in all cases.
To generate AVs, selected bacterial or viral strains are 
usually combined with a proper adjuvant. Several viral 
or bacterial species can be used in a combination vaccine 
and different serotypes can also be combined in a poly‑
valent vaccine. The combination of inactivated viruses 
and bacteria is also an option. Bacterial AVs are accepted 
in all countries of the economic European area, whereas 
viral AVs are not allowed in 10 European countries 
including France, Denmark and Spain [138].
A critical role in the successful production and use of 
an AV falls to the isolation of vaccine strains. Therefore 
diagnostic samples must be carefully obtained, based on 
appropriate choices regarding which sick and untreated 
animals to select for sample collection, which necropsy 
material to select, and which cultivation conditions and 
strains to use after results from sero‑, toxo‑ or virulence‑
typing. For that purpose several methods like PCR, 
MALDI‑TOF MS, slide agglutination or DNA sequenc‑
ing are available. Because of the fundamental importance 
of the strain choice for the production of an adequate AV, 
close collaboration between diagnostic laboratory and 
vaccine production is critical. Each production is cus‑
tom‑made and numerous adjuvants, viral and bacterial 
isolates, including serotypes, toxins and species, provide 
countless combinations. This underlines the importance 
of experience as the basis in the production of high qual‑
ity AVs. The veterinarian also has obligations regarding 
diagnosis, ordering and responsibility for the administra‑
tion of the vaccine.
A variety of bacterial components are often used in 
AVs. These include for poultry: Bordetella spp., Campy-
lobacter spp., Cl. perfringens, Enterococcus cecorum, 
Erysipelothrix rhusiopathiae, E. coli, Gallibacterium 
anatis, Mycoplasma spp., Ornithobacterium rhinotra-
cheale, Pasteurella multocida, Riemerella anatipestifer; 
for swine: Actinobacillus pleuropneumoniae, Bordetella 
spp., Brachyspira spp., Cl. perfringens, E. coli, H. paras-
uis, Mycoplasma spp., Pasteurella multocida, Strep. suis, 
Trueperella pyogenes; for cattle: Chlamydia spp. Cl. Per-
fringens, E. coli, Histophilus somni, Mannheimia haemo-
lytica, Moraxella bovis, Mycoplasma spp., Pasteurella 
multocida, Salmonella enterica, Trueperella pyogenes; 
and for fish: Aeromonas spp., Photobacterium spp., Pseu-
domonas spp., Vibrio spp., Yersinia ruckeri.
Depending on the animal species and age at vaccina‑
tion different adjuvants can be used. As a standard adju‑
vant with good safety and efficacy, aluminium hydroxide 
is often used for production. Polymer and other gel‑like 
adjuvants are also available for production in aqueous 
mixtures. Oily adjuvants, especially for water‑in‑oil emul‑
sions, require a more sophisticated mixing procedure 
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because of the need of a stable emulsion. Furthermore 
oily vaccines might pose safety concerns. However, 
these induce a promising long lasting immune response 
because of a depot effect. In the case of organic animal 
production use of plant oil might be an option in order to 
avoid unwanted hydrocarbons. The risk of adverse effects, 
which depend on the adjuvant‑antigen combination, can 
be decreased by standardization of the protocols.
More data regarding the efficacy and safety of AVs in 
field studies should be collected because clinical safety 
and efficacy is not regulated. The need for this is reflected 
by numerous current publications about viral and bacte‑
rial AVs for poultry [139–142], bovine [143], swine [144] 
and fish [145]. Most results show that AVs can be a useful 
alternative to antibiotic use.
Only a few countries allow the use of live AVs [138]. 
The normally inactivated vaccines must be tested for 
sterility. In the EU this could be carried out by internal 
tests according to the Pharmacopoea [146]. Further steps 
in quality control include the inactivation test, endotoxin 
content or stability tests. Some producers offer GMP 
production, and GMP production is required in some 
countries such as Finland or Sweden [147]. In most coun‑
tries GMP is only recommended. This example shows the 
vast differences in national legislation regarding the defi‑
nition and interpretation of AVs. Because of worldwide 
circulation of animals and their pathogens a harmoniza‑
tion of manufacture, control and use of immunological 
veterinary medicinal products like AV is important, and 
the aim at the economic European area [138].
In summary, AVs are a valuable option in certain situ‑
ations where commercial vaccines are either not avail‑
able or expected to lack efficacy because of a mismatch 
between circulating and vaccine strains. The selection 
of adequate clinical isolates and vaccine formulations 
requires considerable expertise and the effective use of 
AVs depends on adequate manufacturing and appropri‑
ate veterinary oversight. Regulatory differences among 
countries create a highly fragmented legal landscape that 
would benefit from further harmonization.
5  Conclusions
Vaccines are proven strategies for the prevention or con‑
trol of infectious diseases in animal populations. There‑
fore, they are promising alternatives that can reduce the 
need to use antibiotics in food‑producing animals and 
their direct mitigating impact on antibiotic consump‑
tion has been demonstrated in a number of studies, even 
though the relationship between antibiotic use and vac‑
cination is not in all cases clear‑cut. The ideal vaccine is 
safe, effective against a broad range of pathogens, and 
easily adapted to mass‑application. At the same time, it 
is cheap to produce and use, easy to register across key 
jurisdictions, and generates durable protection, ideally 
after a single administration.
Existing vaccines still fall short of these ideals. In fact, 
many current vaccines have a number of shortcomings 
with regard to safety, efficacy and/or user‑friendliness 
that limit their ability to replace antibiotic use. Over‑
coming these challenges will take close collaboration and 
innovative new approaches. Public–private partnerships 
represent one promising governing structure for assuring 
such close collaboration across public and private sectors. 
Investments in basic and applied research are equally 
needed to overcome these challenges, and research needs 
will have to be prioritized to ensure scarce resources will 
be preferentially dedicated to areas of greatest potential 
impact. Research to characterize and quantify the impact 
of vaccination on antibiotic use is equally needed.
Yet, some data demonstrating the ability of vaccines to 
reduce antibiotic consumption are already available. Sim‑
ilarly, key research breakthroughs and a number of highly 
promising vaccination approaches are already in devel‑
opment. These include new oral vaccines based on bac‑
terial spores, live vectors, or new delivery strategies for 
inactivated oral vaccines; they also include new vaccina‑
tion strategies in‑ovo, combination vaccines that protect 
against multiple pathogens, the use of recent biotechno‑
logical advances, and comprehensive approaches to man‑
age diseases caused by ubiquitous pathogens.
Therefore, further reductions in the need for antibiotic 
use through the use of new vaccines are all‑but‑certain, 
and investments in research and development of new 
vaccines will be vital for the sustained success of animal 
agricultural production around the world.
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